Potential new target for reducing osteoporosis risk in men

Researchers have identified a new regulator of vitamin D metabolism that could be targeted to reduce the risk of osteoporosis in men undergoing prostate cancer therapy, according to a study published in theJournal of Molecular Endocrinology.Medical Xpress
Source: Society for Endocrinology - Category: Endocrinology Source Type: news

Related Links:

Conclusions: A home-based exercise program is relatively feasible and safe and may improve muscle strength but not bone outcomes. Implications for Practice: Given the importance of preventing cancer treatment–induced bone loss among PCSs receiving ADT, a home-based exercise intervention can be considered, but further trials with a larger sample are required to determine its effect for bone outcomes.
Source: Cancer Nursing - Category: Nursing Tags: Articles Source Type: research
By MATTHEW HOLT Happy 15th birthday THCB! Yes, 15 years ago today this little blog opened for business and changed my life (and at least impacted a few others). Later this week we are going to celebrate and tell you a bit more about what the next 15 years (really?) of THCB might look like. But for now, I’m rerunning a few of my favorite pieces from the mid-2000s, the golden age of blogging. Today I present “Health Care = Communism + Frappuccinos”, one of my favorites about the relationship between government and private sector originally published here on Jan7, 2005. And like the Medicare one from last we...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Matthew Holt OP-ED 15th Birthday Celebration Commumism Frappuchinos Source Type: blogs
Authors: Gupta T, Das N, Imran S Abstract Osteoporosis is one of the major health problems worldwide. It is characterized by increased bone fragility and loss of bone matter due to the action of osteoclast cells, which are associated with modified hormone levels and factors such as aging. Bisphosphonates are the primary treatment for osteoporosis. Apart from bisphosphonates, hormone therapy, calcitonin treatment, selective estrogen receptor modulators (SERMs), and strontium ranelate (SR) are some of the other treatments available for osteoporosis. However, these treatments have some side effects, such as oily skin,...
Source: Journal of Dietary Supplements - Category: Nutrition Tags: J Diet Suppl Source Type: research
Publication date: Available online 20 March 2018Source: The Lancet Diabetes &EndocrinologyAuthor(s): Tilman D Rachner, Robert Coleman, Peyman Hadji, Lorenz C HofbauerSummaryPreservation of bone health remains a long-term clinical challenge in patients with breast and prostate cancer. Osteoporosis, defined by a loss of bone mass and microarchitecture, often results in fragility fractures that are typically associated with a high socioeconomic burden. Endocrine therapy, a mainstay treatment in the management of patients with hormone-sensitive breast and prostate cancer in the adjuvant setting, commonly exerts adverse eff...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
AbstractA 74-year-old man presented to the Andrology Clinic for management of potential complications of androgen deprivation therapy for prostate cancer. He had a rising prostate-specific antigen with a concurrent rise in alkaline phosphatase and bone remodeling markers. This was despite treatment with a radical prostatectomy, androgen deprivation, and anti-resorptive therapy. A follow-up dual-energy X-ray absorptiometry scan revealed a marked increase in his bone mineral density at both the lumbar spine and femoral neck. This increase, especially in the context of rising bone remodeling markers, was unlikely due to the e...
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
CONCLUSIONS: Comprehensive management of the patient with advanced prostate cancer should include the study and treatment of osteoporosis and bone metastases. Currently, very effective therapies are available for both entities. PMID: 29633946 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Metabolic side effects of androgen deprivation therapy (ADT) include diabetes, weight gain, increased fat mass, and osteoporosis. We previously showed in the CAPS1 trial that restricting carb intake in overweight men starting ADT led to weight and fat mass loss, suggestively improved insulin sensitivity, and reduced bone mass loss, thus reducing the risk of ADT-associated side effects vs. a control arm (no lifestyle changes). Here, we present secondary outcomes. We hypothesized a low-carb diet would favorably impact cholesterol, HbA1c, and HsCRP levels (a measure of systemic inflammation) without increasing adverse events (AEs).
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Advanced (including Drug Therapy) II Source Type: research
In this study, changes in bone quality, turnover markers, and BMD after ADT were prospectively evaluated before and after ADT in castration-sensitive prostate cancer.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Advanced (including  Drug Therapy) IV Source Type: research
Publication date: Available online 20 March 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Tilman D Rachner, Robert Coleman, Peyman Hadji, Lorenz C Hofbauer Preservation of bone health remains a long-term clinical challenge in patients with breast and prostate cancer. Osteoporosis, defined by a loss of bone mass and microarchitecture, often results in fragility fractures that are typically associated with a high socioeconomic burden. Endocrine therapy, a mainstay treatment in the management of patients with hormone-sensitive breast and prostate cancer in the adjuvant setting, commonly exerts adverse effect...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Endocrinology | Orthopaedics | Osteoporosis | Prostate Cancer | Study | Vitamin D | Vitamins